Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses

Emerging Infectious Diseases

Volumn 18, Issue 1, 2012, Pages 109-112

  Hurt, Aeron C ^a   Leang, Sook Kwan ^a   Speers, David J ^b   Barr, Ian G ^a   Maurer Stroh, Sebastian ^c,d,e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c AGENCY FOR SCIENCE   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BINDING; DRUG SENSITIVITY; GENE CONSTRUCT; HUMAN; IC 50; INFLUENZA VIRUS A H1N1; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, MOLECULAR; OSELTAMIVIR; PANDEMICS; PROTEIN CONFORMATION; WORLD HEALTH;

EID: 84856573710     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1801.111079     Document Type: Article

References (15)

1. Hurt AC, Lee R, Leang S, Cui L, Deng Y, Phuah S, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill. 2011;16:pii:19884.
2. Santos L, Correia V, Giria M, Pedro S, Santos M, Silvestre M, et al. Genetic and antiviral drug susceptbility profiles of pandemic A(H1N1)v influenza virus circulating in Portugal. In: Proceedings of Options for the Control of Influenza VII, Hong Kong, SAR, China, September 1-3, 2010. Atlanta (GA): Intregress; 2010. Abstract no. O-851.
3. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug- resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363:1381-2. doi:10.1056/NEJMc1003749
4. Yi H, Lee JY, Hong EH, Kim MS, Kwon D, Choi JH, et al. Oseltamivir- resistant pandemic (H1N1) 2009 virus, South Korea. Emerg Infect Dis. 2010;16:1938-42.
5. Shin SY, Kang C, Gwack J, Kim JH, Kim HS, Kang YA, et al. Drugresistant pandemic (H1N1) 2009, South Korea. Emerg Infect Dis. 2011;17:702-4.
6. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73:228-31. doi:10.1016/j.antiviral.2006.10.004
7. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 2010;6:e1000933. doi:10.1371/journal.ppat.1000933
8. Hurt AC, Holien JK, Parker M, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs. 2009;69:2523-31. doi:10.2165/11531450-000000000-00000
9. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009;53:4433-40. doi:10.1128/AAC.00334-09
10. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 2004;62:37-45. doi:10.1016/j.antiviral.2003.11.008
11. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical interface for the FoldX forcefield. Bioinformatics. 2011;27:1711-2. doi:10.1093/bioinformatics/btr254
12. Krieger E, Koraimann G, Vriend G. Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins. 2002;47:393-402. doi:10.1002/prot.10104
13. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol. 2010;17:1266-8. doi:10.1038/nsmb.1909
14. Peng AW, Milleri S, Stein DS. Direct measurement of the antiinfluenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother. 2000;44:1974-6. doi:10.1128/ AAC.44.7.1974-1976.2000
15. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471-84. doi:10.2165/00003088-199937060-00003